Skip to content

Customers' Unmet Needs and Pains

Pharmaceuticals in Brazil Current Pains Analysis

The synthesis of the four analytical blocks confirms that every customer group in the Brazilian pharmaceutical value chain—individual consumers, retail pharmacies, hospitals/clinics, and the Public Health System (SUS)—faces a dense cluster of structural, economic, and operational pains. These pains spring from Brazil’s heavy import-dependence for active pharmaceutical ingredients (APIs), complex regulation, and the country’s vast geography, culminating in high costs and uneven access to medicines.

1. Cross-Cutting Pains

Pain Core Driver(s) Primary Customer(s) Impacted Manifestation & Consequences
High medicine prices & affordability gap • 90 % API import dependence • Exchange-rate volatility • R&D and compliance costs • Retail mark-ups • Consumers • SUS • Out-of-pocket burden for families • Budget stress for SUS; delayed or restricted formularies
Supply-chain vulnerability & stock-outs • Import delays • Limited domestic API/finished-drug capacity • Pandemic-style shocks • Consumers • Retailers • Hospitals/clinics • SUS • Periodic shortages of critical drugs, especially oncology, antimicrobials, insulin
Logistical complexity in a continental territory • Poor multimodal freight network • Cold-chain requirements • High inland freight cost • Distributors • Retailers • Hospitals/SUS • Slower lead-times, higher freight premiums passed into final prices
Cumbersome, slow regulatory processes (ANVISA) • Back-log of product registration • Frequent rule changes • Inspection bottlenecks • Manufacturers • Importers • Pharmacies/Hospitals • Time-to-market delays; cost inflation; compliance uncertainty
Market consolidation & margin squeeze in retail • Aggressive expansion of top 3 chains (≈40 % share) • Independent pharmacies • Consumers (choice) • Store closures, reduced geographic equity in access
Counterfeit / illicit trade risk • Parallel imports • Weak enforcement in remote regions • Consumers • Retailers • Health risks; brand/reputation loss
Public procurement bureaucracy & budget ceilings • Lengthy tender cycles • Fiscal constraints • SUS • Manufacturers • Late payments; tender deserts; chronic under-supply in some therapeutic classes
Limited domestic innovation pipeline • Low translational R&D • Funding gaps • All segments (access) • Dependence on imported innovative drugs; slow uptake of cutting-edge therapies

2. Pain Hot-Spots by Customer Segment

  1. Individual Consumers
    • Affordability of chronic-disease medication (diabetes, hypertension).
    • Stock-outs of vaccines and paediatric antibiotics in interior regions.
    • Travel distance/time to reach pharmacies offering specialty services (e.g., immunisation).

  2. Retail Pharmacies
    • Margin compression from price-controlled products vs. rising operating costs.
    • Inventory risk for temperature-sensitive drugs amid strict RDC 430/2020 rules.
    • Digital-readiness gap to meet the e-Rx and tele-pharmacy wave.

  3. Hospitals & Clinics
    • Erratic supply of high-cost biologics and oncology injectables.
    • Tight cash flow due to delayed SUS reimbursements and bulk-buy capital lock-in.
    • Complexity of pharmacovigilance/reporting compliance.

  4. Public Health System (SUS)
    • Escalating expenditure on strategic, high-cost drugs (biologics, rare diseases).
    • Tender desertion by suppliers when reference prices are below cost.
    • Need for real-time traceability to curb diversion and theft in the distribution chain.

Unmet Needs and Pains

Drawing on the four analytical streams, the following unmet needs remain insufficiently addressed by current market offerings and policy frameworks:

1. Strategic Resilience & Local Production

• Need: Secure, scalable domestic API and finished-drug manufacturing to lower import exposure and price shocks.
• Pain Signal: 90 % of APIs are imported; 90 % of Brazilians demand more “Made-in-Brazil” medicines.

2. Affordable Access for Chronic & Elderly Patients

• Need: Sustainable pricing models (subscription, value-based, PPPs) and expanded generic/biosimilar penetration.
• Pain Signal: Retail market price readjustments spark consumer backlash; hypertension/diabetes drug spend outpaces income growth among lowest quartile.

3. Agile, Risk-Based Regulation

• Need: Shorter ANVISA approval timelines, greater reliance on international reference authorities, digital dossier submission, and streamlined GMP inspection scheduling.
• Pain Signal: Industry cites regulatory burden as top non-cost barrier; product launch delay averages 12–18 months vs. US/EU.

4. Nationwide Last-Mile Distribution & Cold-Chain Capacity

• Need: Integrated multimodal logistics, real-time temperature tracking, and subsidies for deliveries to Amazon, Northeast hinterlands, and border areas.
• Pain Signal: Recurrent vaccine spoilage incidents; 57 % of retail volume moves via distributors that struggle with refrigerated freight.

5. Digital & Integrated Pharmacy Services

• Need: Omni-channel pharmacy platforms offering e-prescription fulfilment, tele-pharmacy counselling, adherence apps, and at-home diagnostics.
• Pain Signal: Rapid chain expansion but uneven digital maturity; independents lack capital for health-hub transformation.

6. Anti-Counterfeit Traceability (end-to-end)

• Need: Full implementation of Brazil’s National Medicine Control System (SNCM) with GS1 standards, blockchain pilots, and rural enforcement.
• Pain Signal: Surge in online counterfeit seizures; consumer mistrust rises in social-listening sentiment.

7. Procurement Innovation for SUS

• Need: Outcome-based contracts, portfolio tenders, and dynamic purchasing that align supplier economics with public-health goals.
• Pain Signal: Suppliers abandon tenders when price ceilings fall below cost; frequent emergency purchases at premium prices.

8. Incentives for Domestic Innovative R&D

• Need: Tax credits, grant-matching, fast-track orphan-drug pathways, and translational research hubs connecting academia with manufacturers.
• Pain Signal: Only ~1 % of global novel molecules originate in Brazil; dependence on imported biologics inflates SUS budget.

9. Financial & ESG Transparency Across the Chain

• Need: Open-data dashboards on pricing, tender results, and ESG footprints to build trust and guide policy.
• Pain Signal: Public scepticism over price hikes; fragmented data hampers evidence-based decisions.

Key Findings

# Key Insight Evidence Source(s) Strategic Implication
1 Import dependence on APIs (≈90 %) is the single largest systemic vulnerability. CNN Brasil; Agência Gov; Social-listening data (90 % citizen preference for domestic production) Prioritise incentives for local API plants; de-risk supply chain.
2 Medicine affordability remains the top pain for consumers and SUS alike. Abradilan price-readjustment reports; Demand Analysis (8.1 bn retail units, 6 % YoY) Expand generics/biosimilars; explore value-based pricing and bulk-buy discounts.
3 Regulatory timelines and compliance costs inflate final prices and delay access. Anvisa annual report; Industry sentiment in Social Listening Deploy risk-based review, digital submissions, mutual-recognition agreements.
4 Logistical hurdles impede equitable access, especially in remote regions. Omni Hospitalar; Distribution volume data (4.6 bn units); Hospital pain points Invest in cold-chain infrastructure; leverage public-private logistics hubs.
5 Retail market consolidation benefits scale players but threatens independents and consumer choice. Febrafar; Medicina SA (top 3 chains = 40 % share) Support coop buying groups; promote digital solutions for independents.
6 Counterfeit risk erodes trust and poses safety threats. Anvisa seizures; Social sentiment analysis Accelerate SNCM implementation; stronger enforcement & tech (blockchain, QR).
7 SUS procurement rigidity causes supplier drop-out and shortages. SUS tender analyses; Customer-pain block Pilot outcome-based contracts; adjust reference pricing more dynamically.
8 Domestic innovative R&D output is low despite high absolute R&D spend. BNDES; InvesteSP; Grupo FarmaBrasil Enhance translational research, public-private co-development, fast-track orphan-drug paths.

References

(Note: Only publicly accessible URLs have been included; URLs from the “vertexaisearch.cloud.google.com” domain were omitted.)

  1. CNN Brasil. “Brasil importa 90% da matéria-prima para a produção de medicamentos.” https://www.cnnbrasil.com.br/economia/brasil-importa-90-da-materia-prima-para-producao-de-medicamentos/
  2. Agência GOV. “Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos.” https://www.gov.br/pt-br/noticias/industria-e-comercio/2024/01/nova-industria-brasil-contribuira-para-fortalecer-producao-de-medicamentos
  3. Anvisa. “Anuário da Indústria Farmacêutica 2023.” https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/anuarios/industria-farmaceutica-2023.pdf
  4. Abradilan. “Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas.” https://abradilan.com.br/noticias/setor-farmaceutico-cresce-127-em-2024
  5. Omni Hospitalar. “Como funciona o processo de distribuição de medicamentos?” https://omnihospitalar.com.br/blog/processo-de-distribuicao-de-medicamentos
  6. Febrafar. “Varejo farmacêutico: destaques de 2024 e expectativas para 2025.” https://febrafar.com.br/noticias/varejo-farmaceutico-2024
  7. Medicina SA. “Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil.” https://revistamedicinasa.com.br/mercado/tres-grandes-grupos-de-redes-de-farmacias-concentram-40-do-mercado
  8. VEJA. “90% dos brasileiros dizem que produção nacional de remédios deve aumentar.” https://veja.abril.com.br/economia/90-dos-brasileiros-querem-remedios-nacionais
  9. Grupo FarmaBrasil. “Pesquisa, desenvolvimento e inovação no setor farmacêutico brasileiro.” https://grupofarmabrasil.com.br/estudos/pesquisa-e-inovacao-no-setor-farmaceutico
  10. BNDES. “Cadeia farmacêutica no Brasil: avaliação preliminar e perspectivas.” https://www.bndes.gov.br/wps/wcm/connect/site/9b123d7e-d0d4-4fbb-8be8-fc8a6f2dc2b6/
  11. InvesteSP. “Setor farmacêutico é o que mais investe em P&D.” https://www.investe.sp.gov.br/noticia/setor-farmaceutico-lidera-investimentos-em-pd
  12. Omni Hospitalar. “Distribuição refrigerada e desafios logísticos.” https://omnihospitalar.com.br/blog/distribuicao-refrigerada-medicamentos
  13. Vernalha Pereira. “Novas regras da Anvisa e o impacto no registro de medicamentos.” https://vernalhapereira.com.br/artigos/anvisa-impacto-registro

(Additional references cited in the four analytical documents were consulted for qualitative insights but are not listed here to avoid duplications without publicly verifiable URLs.)